Zilpaterol hydrochloride - Anses - Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail Access content directly
Other Publications Year : 2016

Zilpaterol hydrochloride


The 78th meeting of the Committee, at the request of the 21st Session of CCRVDF (FAO/WHO, 2014a), evaluated zilpaterol HCl and established an ADI of 0–0.04 µg/kg bw on the basis of a LOAEL for a slight increase of tremor in humans in a single dose study (FAO/WHO, 2014b). The 78th meeting of the Committee also agreed that parent zilpaterol was an appropriate marker residue in muscle. Only limited data were available for tissues other than muscle, and the Committee was unable to determine a suitable marker residue in other edible tissues. Liver and kidney contained the highest concentration of zilpaterol at all sampling times, followed by muscle. The ratios of the concentration of zilpaterol to the concentration of the total residues for liver and for kidney over the 96-hour withdrawal period after the last drug administration could not be determined with any confidence due to the very limited data available and lack of sensitivity of the methods used. The data provided were not sufficient to determine the total residue half-life in the liver after 96 hours. There are no measurable residues in adipose fat.
Fichier principal
Vignette du fichier
joe147.pdf (6.11 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

anses-01335049 , version 1 (21-06-2016)


  • HAL Id : anses-01335049 , version 1


Joe Boison, Pascal Sanders, Alan Chicoine, Stefan Scheid. Zilpaterol hydrochloride. 2016. ⟨anses-01335049⟩


331 View
618 Download


Gmail Facebook X LinkedIn More